JP7043114B2 - 細胞を活性化させるための方法およびキット - Google Patents

細胞を活性化させるための方法およびキット Download PDF

Info

Publication number
JP7043114B2
JP7043114B2 JP2019510693A JP2019510693A JP7043114B2 JP 7043114 B2 JP7043114 B2 JP 7043114B2 JP 2019510693 A JP2019510693 A JP 2019510693A JP 2019510693 A JP2019510693 A JP 2019510693A JP 7043114 B2 JP7043114 B2 JP 7043114B2
Authority
JP
Japan
Prior art keywords
cells
dna
cell
act
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019510693A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534684A (ja
JP2019534684A5 (enExample
Inventor
コヴァックス，アーネスト・ウィリアム
スード，アヌープ
スミス，レジナルド・ドノヴァン
ロギン，エヴリナ・ロクサーナ
チャウドゥーリ，パドマパルナ
ケスカー，ヴァンダナ
チャドウィック，クリスタル・メイ
ブラウン，マーティン・ジェームス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Global Life Sciences Solutions USA LLC
Original Assignee
Amersham Biosciences Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amersham Biosciences Corp filed Critical Amersham Biosciences Corp
Publication of JP2019534684A publication Critical patent/JP2019534684A/ja
Publication of JP2019534684A5 publication Critical patent/JP2019534684A5/ja
Application granted granted Critical
Publication of JP7043114B2 publication Critical patent/JP7043114B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/51—B7 molecules, e.g. CD80, CD86, CD28 (ligand), CD152 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019510693A 2016-08-24 2017-08-24 細胞を活性化させるための方法およびキット Active JP7043114B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/245,584 2016-08-24
US15/245,584 US10294454B2 (en) 2016-08-24 2016-08-24 Methods and kits for cell activation
PCT/US2017/048306 WO2018039400A1 (en) 2016-08-24 2017-08-24 Methods and kits for cell activation

Publications (3)

Publication Number Publication Date
JP2019534684A JP2019534684A (ja) 2019-12-05
JP2019534684A5 JP2019534684A5 (enExample) 2020-07-30
JP7043114B2 true JP7043114B2 (ja) 2022-03-29

Family

ID=59914514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510693A Active JP7043114B2 (ja) 2016-08-24 2017-08-24 細胞を活性化させるための方法およびキット

Country Status (5)

Country Link
US (2) US10294454B2 (enExample)
EP (1) EP3504323A1 (enExample)
JP (1) JP7043114B2 (enExample)
CN (1) CN109563484A (enExample)
WO (1) WO2018039400A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation
GB201820444D0 (en) * 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
CN110184239B (zh) * 2019-06-12 2021-04-06 蓝莲(杭州)生物科技有限公司 一种活性化t淋巴细胞培养液及其活性化t淋巴细胞的制备方法
EP4172318A4 (en) * 2020-06-29 2024-08-07 Stemcell Technologies Canada Inc. COMPOSITIONS, SYSTEMS AND METHODS FOR STIMULATING CELLS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
JP2015533493A (ja) 2012-09-25 2015-11-26 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 可動性ナノマトリックスによるｔ細胞のポリクローナル刺激方法
WO2016033690A1 (en) 2014-09-04 2016-03-10 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3825615A1 (de) 1988-07-28 1990-02-01 Behringwerke Ag Antigenkonstrukte von "major histocompatibility complex" klasse i antigenen mit spezifischen traegermolekuelen, ihre herstellung und verwendung
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US7479269B2 (en) 1988-11-23 2009-01-20 Genetics Institute, Llc Methods for selectively enriching TH1 and TH2 cells
JP2618497B2 (ja) 1989-10-03 1997-06-11 鐘淵化学工業株式会社 腫瘍障害細胞誘導剤および腫瘍障害細胞誘導デバイス
US5872222A (en) 1991-04-19 1999-02-16 Tanox Biosystems, Inc. Conjugates of polymers and antibodies specific for T lymphocytes, and their use as adjuvants
US6106835A (en) 1991-04-19 2000-08-22 Tanox, Inc. Modified binding molecules specific for T or B lymphocytes and their use as in vivo immune modulators
US6129916A (en) 1991-04-19 2000-10-10 Tanox, Inc. Method of Increasing activation on proliferation of T cells using antibody-microbead conjugates
CA2065658A1 (en) 1991-04-19 1992-10-20 Tse-Wen Chang Conjugates of liposomes or microbeads and antibodies specific for t lymphocytes and their use in vivo immune modulators
US6197298B1 (en) 1991-04-19 2001-03-06 Tanox, Inc. Modified binding molecules specific for T lymphocytes and their use as in vivo immune modulators in animals
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
AU5729294A (en) 1992-11-25 1994-06-22 Tanox Biosystems, Inc. Conjugates and constructs including anti-cd28 and anti-cd3 binding molecules
DE69418699T2 (de) 1993-01-11 1999-09-30 Dana-Farber Cancer Institute, Boston Induktion der antworten zytotoxischer t-lymphozyten
CA2164226C (en) 1993-06-04 2011-02-08 Carl H. June Methods for selectively stimulating proliferation of t cells
AU6920194A (en) 1993-06-11 1995-01-03 Coulter Corporation Anti-cd3 antibody-aminodextran conjugates for induction of t-cell activation and proliferation
US5635602A (en) 1993-08-13 1997-06-03 The Regents Of The University Of California Design and synthesis of bispecific DNA-antibody conjugates
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
WO1995033823A1 (en) 1994-06-03 1995-12-14 The United States Of America, Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of t cells
US7074904B2 (en) 1994-07-29 2006-07-11 Altor Bioscience Corporation MHC complexes and uses thereof
WO1996027392A1 (en) 1995-03-08 1996-09-12 The Scripps Research Institute Antigen presenting system and methods for activation of t-cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
ATE292689T1 (de) 1995-05-04 2005-04-15 Us Navy Verbesserte verfahren zur transfektion der t- zellen
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
JPH11507843A (ja) 1996-03-28 1999-07-13 ザ・ジョンズ・ホプキンス・ユニバーシティー タンパク質の可溶性二価および多価ヘテロ二量体類縁体
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US7973137B1 (en) 1996-03-28 2011-07-05 Johns Hopkins University Cell compositions comprising molecular complexes that modify immune responses
ES2277358T3 (es) 1996-09-06 2007-07-01 Ortho-Mcneil Pharmaceutical, Inc. Purificacion de celulas t especificas de antigeno.
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
US6077833A (en) 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7927595B1 (en) 1997-02-21 2011-04-19 The United States Of America As Represented By The Secretary Of The Navy Methods for downregulating CCR5 in T cells with anti-CD3 antibodies and anti-CD28 antibodies
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6248564B1 (en) 1997-08-29 2001-06-19 Harvard University Mutant MHC class I molecules
AU741130B2 (en) 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
US6232445B1 (en) 1997-10-29 2001-05-15 Sunol Molecular Corporation Soluble MHC complexes and methods of use thereof
ES2279600T3 (es) 1998-03-12 2007-08-16 Miltenyi Biotec Gmbh Sistema de microcolumna para separacion magnetica.
US7264965B2 (en) 1998-06-05 2007-09-04 Alexis Biotech Limited Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US20020051783A1 (en) 1998-06-05 2002-05-02 Savage Philip Michael Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
US7521197B2 (en) 1998-06-05 2009-04-21 Alexis Biotech Limited Method for producing cytotoxic T-cells
GB2339782A (en) 1998-06-05 2000-02-09 Philip Michael Savage Chimeric protein complexes comprising HLA class I antigens
US6787154B2 (en) 1998-10-20 2004-09-07 Salvatore Albani Artificial antigen presenting cells
DE69942100D1 (de) 1998-10-20 2010-04-15 Androclus Technologies S R L I Künstliche antigen-spezifischen zellen und zugehörige verfahren
US6590076B1 (en) 1999-04-02 2003-07-08 Corixa Corporation Compositions for the treatment and diagnosis of breast cancer and methods for their use
HK1052372A1 (zh) 2000-02-24 2003-09-11 Xcyte Therapies, Inc. 细胞的同步刺激和富集
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US20030119185A1 (en) 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
EP1526171A1 (en) 2000-02-24 2005-04-27 Xcyte Therapies, Inc Simultaneous stimulation and concentration of cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
US20030235908A1 (en) 2000-02-24 2003-12-25 Xcyte Therapies, Inc. Activation and expansion of cells
WO2002042447A2 (en) 2000-11-03 2002-05-30 Regents Of The University Of Michigan Surface transfection and expression procedure
US6902933B2 (en) 2000-11-03 2005-06-07 Regents Of The University Of Michigan Surface transfection and expression procedure
US6897067B2 (en) 2000-11-03 2005-05-24 Regents Of The University Of Michigan Surface transfection and expression procedure
EP1227321A1 (en) 2000-12-28 2002-07-31 Institut für Bioanalytik GmbH Reversible MHC multimer staining for functional purification of antigen-specific T cells
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
WO2003057171A2 (en) 2002-01-03 2003-07-17 The Trustees Of The University Of Pennsylvania Activation and expansion of t-cells using an engineered multivalent signaling platform
CN100379852C (zh) * 2002-02-08 2008-04-09 埃克斯西特治疗公司 用于在免疫缺陷患者体内恢复免疫响应的组合物和方法
JP2005517025A (ja) 2002-02-08 2005-06-09 エクサイト セラピーズ， インコーポレイテッド 免疫学的欠損を有する患者において免疫応答性を回復するための、組成物および方法
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
ES2422193T3 (es) 2002-06-28 2013-09-09 Life Technologies Corp Métodos para restaurar el repertorio inmune en pacientes con defectos inmunológicos relacionados con la autoinmunidad y trasplante de órganos o de células madre hematopoyéticas
US20040175373A1 (en) 2002-06-28 2004-09-09 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
US20040115216A1 (en) 2002-07-12 2004-06-17 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
WO2004104185A1 (en) 2003-05-08 2004-12-02 Xcyte Therapies, Inc. Generation and isolation of antigen-specific t cells
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US7402431B2 (en) 2004-03-01 2008-07-22 Immunovative Therapies, Ltd. T-cell therapy formulation
WO2005049085A1 (en) 2003-11-18 2005-06-02 Valeocyte Therapies Llc Use of soluble complexes to facilitate cell activation
JP2008504216A (ja) 2003-12-02 2008-02-14 サイトイミューン サイエンシズ インコーポレイテッド モノクローナル抗体の生成のための方法および組成物
JP2007525225A (ja) 2004-02-26 2007-09-06 イミュノバティブ セラピーズ， リミテッド 細胞治療のためのｔ細胞を調製するための方法
US7592431B2 (en) 2004-02-26 2009-09-22 Immunovative Therapies, Ltd. Biodegradable T-cell Activation device
ATE449161T1 (de) 2004-03-04 2009-12-15 Leukocare Ag Leukozytenstimulations-matrix
GB2422834B8 (en) 2005-02-04 2007-01-04 Proimmune Ltd MHC oligomer and method of making the same
GB0603081D0 (en) 2006-02-15 2006-03-29 Dynal Biotech Asa Oslo Method
GB2442048B (en) 2006-07-25 2009-09-30 Proimmune Ltd Biotinylated MHC complexes and their uses
CN101548008B (zh) 2006-10-04 2013-04-17 詹森药业有限公司 失活的人工抗原提呈细胞的制备及其在细胞疗法中的用途
EP2155782A2 (en) 2007-03-26 2010-02-24 Dako Denmark A/S Mhc peptide complexes and uses thereof in infectious diseases
US20100143905A1 (en) 2007-03-29 2010-06-10 Lane Michael J Methods and compositions for multivalent binding and methods for manufacture of rapid diagnostic tests
US8629098B2 (en) 2008-01-15 2014-01-14 Yale University Compositions and methods for adoptive and active immunotherapy
US8658178B2 (en) 2008-03-19 2014-02-25 Yale University Carbon nanotube compositions and methods of use thereof
WO2010037395A2 (en) 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
WO2011050000A2 (en) 2009-10-20 2011-04-28 The Regents Of The University Of California Single molecule nucleic acid nanoparticles
GB201002730D0 (en) 2010-02-18 2010-04-07 Uni I Oslo Product
WO2012024695A1 (en) 2010-08-20 2012-02-23 Life Technologies Corporation Magnetic beads having surface glycoconjugates and use thereof
US10023657B2 (en) 2010-10-01 2018-07-17 Ludwig Institute For Cancer Research Ltd. Reversible protein multimers, methods for their production and use
ES2682750T5 (en) 2011-07-18 2025-02-04 Iba Lifesciences Gmbh Method of reversibly staining a target cell
US8834889B2 (en) 2011-08-29 2014-09-16 National Tsing Hua University Antigen presenting composition and use thereof
US10758487B2 (en) 2011-12-09 2020-09-01 The Johns Hopkins University Artificial antigen presenting cells having a defined and dynamic shape
KR101981360B1 (ko) 2012-01-17 2019-05-22 크로다 인코포레이티드 시일 팽윤 첨가제
SG11201404991YA (en) 2012-02-23 2014-09-26 Stage Cell Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
EP2920204B1 (en) 2012-11-16 2019-09-18 IBA GmbH Streptavidin muteins and methods of using them
EP2956481B1 (en) 2013-02-15 2020-07-01 The Johns Hopkins University Antigen-specific t cell redirectors
MX376790B (es) 2013-03-14 2025-03-07 Univ Johns Hopkins Células presentadoras de antígeno artificiales de nanoescala.
US20160017058A1 (en) 2013-03-14 2016-01-21 The California Institute For Biomedical Research Bispecific antibodies and uses thereof
AU2014302784B2 (en) 2013-06-24 2020-01-23 Neximmune Compositions and methods for immunotherapy
ES2612918T3 (es) * 2013-07-10 2017-05-19 Miltenyi Biotec Gmbh Método para inducir la proliferación de células asesinas naturales por nanomatrices móviles
JP5799058B2 (ja) 2013-07-30 2015-10-21 三桜工業株式会社 負圧ポンプ及びシリンダヘッドカバー
RS62471B1 (sr) 2014-04-16 2021-11-30 Juno Therapeutics Gmbh Metode, kompleti i uređaji za proširenje populacije ćelija
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006345852A (ja) 2005-06-16 2006-12-28 Virxsys Corp 抗体複合体
JP2015533493A (ja) 2012-09-25 2015-11-26 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 可動性ナノマトリックスによるｔ細胞のポリクローナル刺激方法
WO2016033690A1 (en) 2014-09-04 2016-03-10 Stemcell Technologies Inc. Soluble antibody complexes for t cell or nk cell activation and expansion

Also Published As

Publication number Publication date
EP3504323A1 (en) 2019-07-03
WO2018039400A1 (en) 2018-03-01
US20200181572A1 (en) 2020-06-11
US20180057791A1 (en) 2018-03-01
CN109563484A (zh) 2019-04-02
JP2019534684A (ja) 2019-12-05
US10294454B2 (en) 2019-05-21
US11512288B2 (en) 2022-11-29

Similar Documents

Publication Publication Date Title
AU2018292181B2 (en) Cellular immunotherapy for repetitive administration
US20230108584A1 (en) Methods for activation and expansion of tumor infiltrating lymphocytes
JP2021534783A (ja) キメラ抗原受容体発現細胞を作製する方法
TW202241508A (zh) 細胞介素相關之腫瘤浸潤性淋巴球組合物及方法
CA3162272A1 (en) Methods for activation and expansion of tumor infiltrating lymphocytes
JP2021518760A (ja) 対になったｃｒｉｓｐｒニッカーゼリボ核タンパク質を用いる免疫関連ゲノムの遺伝子座の改変
JP2018512162A5 (enExample)
WO2021095012A1 (en) Methods of manufacturing car-t cells
US11512288B2 (en) Methods and kits for cell activation
JP2024512608A5 (enExample)
CN114929862A (zh) 用于制备表达嵌合抗原受体的t细胞的生产方法
JP2025529177A (ja) 低免疫原性を操作するための材料及び方法
US20190249141A1 (en) Methods for Generating Functional Therapeutic B Cells ex-vivo
JP2024512029A (ja) Ｔ細胞共培養効力アッセイのための方法及び組成物、ならびに細胞療法製品との使用
CN117480246A (zh) 用于t细胞共培养物效力测定和配合细胞疗法产品使用的方法和组合物
US20250019655A1 (en) Cd28 t cell cultures, compositions, and methods of using thereof
CN121759468A (zh) 一种核酸适配体及其用途
CN116133681A (zh) 用于刺激细胞的组合物、系统和方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190527

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190515

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20190527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200619

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200619

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20201125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210921

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220214

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220310

R150 Certificate of patent or registration of utility model

Ref document number: 7043114

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250